Rhumatologie

No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study

Poster – 69ème Congrès ACR – San Diego (Californie- USA) – 15-17/12/2005 Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller Ziegler L, Pham T, Flipo RM, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Saraux A, Mariette X, Baleydier A, Dougados M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs  in Rheumatoid Arthritis: Results from the 2‑Year  Longitudinal Prospective Non‑interventional  STRATEGE2 Study
Actualités RCTS - Publications - Rhumatologie - Facultatif

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2‑Year Longitudinal Prospective Non‑interventional STRATEGE2 Study

methotrexate maintenance RA
Actualités RCTS - Publications - Rhumatologie - Facultatif

Methotrexate Maintenance RA: STRATEGE2 2‑Year Study

Publication Bias in Drug Safety: RCTs Study on Bisphosphonates
Publications - Success stories - Rhumatologie - Facultatif

Publication Bias in Drug Safety: RCTs Study on Bisphosphonates